1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Upexi reported results for the fiscal year ended June 30, 2026, in a press release furnished as Exhibit 99.1. Total revenue rose to about $25.0 million from $15.8 million, but the net loss grew to $246.1 million, or $3.87 per share, from $13.7 million, or $1.73 per share, mainly due to $195.1 million of unrealized losses on digital assets, so shareholders face a much larger reported loss despite higher revenue.
Total revenue was about $25.0 million for fiscal 2026, compared with $15.8 million for fiscal 2025; digital asset revenue totaled $17.4 million.
Net loss was $246.1 million, or $3.87 per share, versus $13.7 million, or $1.73 per share, a year earlier, driven by $195.1 million of unrealized losses on digital assets.
General and administrative expenses rose to $26.4 million from $11.9 million, primarily reflecting the build-out of the treasury strategy.
Subsequent to year-end, the credit facility with BitGo Prime, LLC was amended to reduce the interest rate from 11.5% to 7.5% per year.
Lisata Therapeutics acquired Marea Therapeutics on September 17, 2026, issuing 1,793,129 shares of common stock and 211,365.213 shares of Series C convertible preferred stock to Marea stockholders. A concurrent private placement is expected to raise about $225 million in gross proceeds, and the filing says pre-transaction Lisata stockholders will hold about 2.39% of the company's common stock after the financing, which substantially dilutes existing holders.
Lisata issued 1,793,129 common shares and 211,365.213 Series C preferred shares to Marea stockholders; each preferred share converts into 1,000 common shares, subject to Lisata stockholder approval
Concurrent private placement with a gross value of about $225 million; the investors will receive Series C preferred shares at about $1,491.37 per share
Post-financing ownership: pre-transaction Lisata holders about 2.39%, former Marea holders about 59.54%, private placement investors about 38.07%
Lisata's CEO is Dr. David J. Mazzo; Dr. Josh Lehrer was newly appointed President and Chief Operating Officer of Lisata
Surgery Partners completed the sale of its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health on September 14, 2026, receiving aggregate consideration of about $796.6 million, with proceeds mainly used to pay down debt. Pro forma figures show lower revenue and a larger net loss attributable to the company for the periods presented, while management expects the deal to be accretive to adjusted earnings growth on an annual basis and to reduce balance sheet leverage. The company also updated its 2026 guidance to remove the sold hospitals' contribution for the rest of the year.
Sale closed September 14, 2026; gross proceeds of $797 million and $587 million in net cash proceeds at closing, subject to post-closing adjustments.
Balance sheet leverage, as defined in the credit agreement, is expected to improve by 30 basis points from 4.4x at the end of Q2 2026.
Updated 2026 guidance: revenue of $3.08 billion to $3.18 billion and Adjusted EBITDA of at least $489 million.
Pro forma net loss attributable to Surgery Partners was $69.2 million for the six months ended June 30, 2026, versus $50.9 million as reported; estimated gain on sale is $16.4 million.
On September 15, 2026, Hallador Energy and subsidiary Turtle Creek Gas Holdings closed a $600 million senior secured term loan with Kennedy Lewis Investment Management, with $550 million funded at closing. The company says the loan will fund turbine payments, development costs and construction of the 460-megawatt Turtle Creek gas project, which has an expected total cost of less than $800 million, but borrowings carry high interest rates and are secured by substantially all company and subsidiary assets.
$600 million senior secured term loan, with $550 million funded at closing and a $50 million delayed draw available for 12 months
Interest is 3.5% cash plus SOFR plus 4.50% payable in kind before commercial operation, then SOFR plus 8.00% in cash after operation begins
Loan matures three years after closing, with a two-year extension option requiring a 3.0% extension fee
Covenants include minimum unrestricted cash of $10 million starting with the test period ending December 31, 2026
Aethlon Medical and private biotech North Immunology signed a merger agreement in which North Immunology becomes a wholly owned subsidiary of Aethlon and the combined company is renamed North Immunology, Inc. Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company, while Aethlon stockholders also receive contingent value rights tied to proceeds, if any, from a sale or other monetization of its legacy Hemopurifier business.
Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company; North Immunology holders, including Private Placement investors, about 95.25%
Concurrent private placement expected to provide about $180 million, including about $34 million from converted notes; closing requires at least $175 million in proceeds
Expected to close in the first quarter of 2027; either party may terminate if not closed by June 17, 2027; termination fees are $300,000 (Aethlon) and $2,000,000 (North Immunology) in specified cases
Combined company expected to trade on Nasdaq Capital Market under ticker NRTX and be led by North Immunology's CEO
Ispire reported fiscal fourth-quarter revenue of $26.7 million, up 33% from a year earlier, and a net loss of $13.8 million ($0.24 per share), versus $14.8 million a year ago. For fiscal 2026, revenue fell 24.7% to $96.0 million, though the net loss narrowed to $33.2 million, and the company said the timing of reaching positive cash flow is now less certain because of Malaysia facility investments.
Q4 revenue $26.7 million vs. $20.1 million a year earlier; gross margin 6.3% vs. 12.3%, hit by inventory impairments
Fiscal 2026 revenue $96.0 million vs. $127.5 million; net loss $33.2 million ($0.58 per share) vs. $39.2 million
Company previously expected positive cash flow in the second half of calendar 2026; it now says timing is less certain
Cash of $19.3 million at June 30, 2026; total stockholders' deficit of $29.2 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.